Brown, S, Barraclough, B, Inskip, H.
Causes of the excess mortality of schizophrenia. Br J Psychiatry
2000; 177: 212–7.
Angst, F, Stassen, HH, Clayton, PJ, Angst, J.
Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord
2002; 68: 167–81.
Sukanta, S, Chant, D, McGrath, J.
A systematic review of mortality in schizophrenia is the differential mortality gap worsening over time?
Arch Gen Psychiatry
2007; 64: 1123–31.
Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry
1997; 171: 502–8.
Hoang, U, Stewart, R, Goldacre, MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ
2011; 343: d5422.
De Hert, M, Dekker, JM, Wood, D, Kahl, KG, Holt, RIG, Möller, HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry
2009; 24: 412–24.
Alberti, KGMM, Zimmet, P, Shaw, J.
The metabolic syndrome – a new worldwide definition. Lancet
2005; 366: 1059–62.
Khatana, SAM, Kane, J, Taveira, TH, Bauer, MS, Wen-Chih, W.
Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS One
2011; 6: 1–8.
Daumit, G, Goff, D, Meyer, J, Davis, V, Nasrallah, H, McEvoy, J, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res
2008; 105: 175–87.
Umbricht, DSG, Pollack, S, Kane, JM. Clozapine and weight gain. J Clin Psychiatry
1994; 55: 157–60.
Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry
1999; 156: 1686–96.
Akhtar, S, Kelly, C, Gallagher, A, Petrie, JR. Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk. Br J Diab Vasc Dis
2004; 4: 303–9.
Newcomer, JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs
2005; 19: 1–93.
Krane-Gartiser, K, Breum, L, Glümrr, C, Linneberg, A, Madsen, M, Køster, A, et al. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry
2011; 65: 345–52.
Correll, CU, Druss, BG, Lombardo, I, O'Gorman, C, Harnett, JP, Sanders, KN, et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv
2010; 61: 892–8.
Gumber, R, Abbas, M, Minajagi, M.
Monitoring the metabolic side-effects of atypical antipsychotics. Psychiatrist
2010; 34: 390–5.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems (10th revision) (ICD-10). WHO, 1992.
British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. BMJ Group, Pharmaceutical Press.
Yorston, G, Pinney, A.
Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatr Bull
2000; 24: 130–2.
Nathan, DM, Balkau, B, Bonora, E, Borch-Johnsen, K, Buse, JB, Colagiuri, S, et al. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. CPD Bull Clin Biochem
2010; 10: 25–33.
Villegas, R, Perry, IJ, Creagh, D, Hinchion, R, O'Halloran, D.
Prevalence of the metabolic syndrome in middle-aged men and women. Diab Care
2003; 26: 3198–9.
Ahmed, M, Hussain, I, O'Brien, SM, Dineen, B, Griffin, D, McDonald, C.
Prevalence and associations of the metabolic syndrome among patients prescribed clozapine. Ir J Med Sci
2008; 177: 205–10.
Mackin, P, Bishop, D, Watkinson, H, Gallagher, P, Ferrier, IN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry
2007; 191: 23–9.
Vinberg, M, Madsen, M, Breum, L, Kessing, LV, Fink-Jensen, A.
Metabolic syndrome in a cohort of affectively ill patients, a naturalistic study. Nord J Psychiatry
2012; 66: 142–5.
John, AP, Koloth, R, Dragovic, M, Lim, SCB. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Australia
2009; 190: 176–9.
De Hert, M, van Winkel, R, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, A, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health
2006; 2: 14.
Management of people with schizophrenia in primary care. Adv Psychiatr Treat
1998; 4: 46–52.
Bainbridge, E, Gallagher, A, McDonald, G, McDonald, C, Ahmed, M.
General practitioners' attitudes on who should manage metabolic dysregulations associated with antipsychotics. Psychiatrist
2011; 35: 213–5.
De Hert, M, Vancampfort, D, Correll, CU, Mercken, V, Peuskens, J, Sweers, K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry
2011; 199: 99–105.
Tosh, G, Clifton, A, Bachner, M.
General physical health advice for people with serious mental illness. Cochrane Database Syst Rev
2011; 2: CD008567.
De Hert, M, Schreurs, V, Vancampfort, D, Van Winkel, R.
Metabolic syndrome in people with schizophrenia: a review. World Psychiatry
2009; 8: 15–22.
Holt, RIG, Abdelrahman, T, Hirsch, M, Dhesi, Z, George, T, Blincoe, T, et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol
2010; 24: 867–73.
Evans, S, Newton, R, Higgins, S.
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry
2005; 39: 479–86.